MX342879B - Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen. - Google Patents

Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen.

Info

Publication number
MX342879B
MX342879B MX2013001201A MX2013001201A MX342879B MX 342879 B MX342879 B MX 342879B MX 2013001201 A MX2013001201 A MX 2013001201A MX 2013001201 A MX2013001201 A MX 2013001201A MX 342879 B MX342879 B MX 342879B
Authority
MX
Mexico
Prior art keywords
same
quinoline derivatives
inhibitors containing
melk inhibitors
melk
Prior art date
Application number
MX2013001201A
Other languages
English (en)
Other versions
MX2013001201A (es
Inventor
Yusuke Nakamura
Joel R Walker
Yo Matsuo
Shoji Hisada
Feryan Ahmed
Raymond Huntley
Helene Decornez
Original Assignee
Oncotherapy Science Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc * filed Critical Oncotherapy Science Inc *
Publication of MX2013001201A publication Critical patent/MX2013001201A/es
Publication of MX342879B publication Critical patent/MX342879B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invención se dirige a un compuesto representado por la fórmula (I).
MX2013001201A 2010-07-30 2011-07-28 Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen. MX342879B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36951910P 2010-07-30 2010-07-30
PCT/US2011/045792 WO2012016082A1 (en) 2010-07-30 2011-07-28 Quinoline derivatives and melk inhibitors containing the same

Publications (2)

Publication Number Publication Date
MX2013001201A MX2013001201A (es) 2013-04-03
MX342879B true MX342879B (es) 2016-10-14

Family

ID=45530500

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001201A MX342879B (es) 2010-07-30 2011-07-28 Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen.

Country Status (16)

Country Link
US (1) US9120749B2 (es)
EP (1) EP2597955B1 (es)
JP (1) JP5849303B2 (es)
KR (1) KR101826382B1 (es)
CN (1) CN103153063B (es)
AU (1) AU2011282588B2 (es)
BR (1) BR112013002182B8 (es)
CA (1) CA2806332C (es)
DK (1) DK2597955T3 (es)
ES (1) ES2565627T3 (es)
IL (1) IL223871A (es)
MX (1) MX342879B (es)
RU (1) RU2582610C2 (es)
SG (2) SG187633A1 (es)
TW (1) TWI532483B (es)
WO (1) WO2012016082A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2635279A4 (en) * 2010-11-05 2014-10-29 Glaxosmithkline Ip No 2 Ltd CHEMICAL COMPOUNDS
DK2753329T3 (en) 2012-01-19 2017-10-23 Onco Therapy Science Inc 1,5-NAPHTHYRIDINE INGREDIENTS AS MILK INHIBITORS
WO2014143659A1 (en) 2013-03-15 2014-09-18 Araxes Pharma Llc Irreversible covalent inhibitors of the gtpase k-ras g12c
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
US10254283B2 (en) 2013-11-12 2019-04-09 Dana-Farber Cancer Institute, Inc. Biomarker for MELK activity and methods of using same
CN105829293B (zh) * 2013-12-20 2018-11-09 中国人民解放军军事医学科学院毒物药物研究所 新型哌啶氨甲酰类化合物、制备方法及其用途
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2016100347A2 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of Michigan Small molecule inhibitors of egfr and pi3k
CA2975277A1 (en) 2015-03-04 2016-09-09 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors of melk and methods of use
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
ES2856880T3 (es) 2015-04-15 2021-09-28 Araxes Pharma Llc Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
CN108026046B (zh) * 2015-07-22 2021-12-21 亚瑞克西斯制药公司 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途
CA2993013A1 (en) * 2015-07-22 2017-01-26 Araxes Pharma Llc Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
BR112018001960A2 (pt) * 2015-08-03 2018-09-18 Bristol-Myers Squibb Company compostos heterocíclicos úteis como moduladores de tnf alfa
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356353A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
KR20180103053A (ko) * 2015-12-22 2018-09-18 비타이 파마슈티컬즈, 인코포레이티드 메닌-mll 상호작용의 억제제
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
SMT202200465T1 (it) 2016-07-14 2023-01-13 Crinetics Pharmaceuticals Inc Modulatori della somatostatina e loro usi
SG10202100683RA (en) 2016-08-31 2021-03-30 Oncotherapy Science Inc Monoclonal antibody against melk and utilization thereof
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
EP3558321B1 (en) * 2016-12-23 2023-02-01 Felicitex Therapeutics, Inc. Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140600A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused hetero-hetero bicyclic compounds and methods of use thereof
KR20200010306A (ko) 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
CN110869357A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 化合物及其用于治疗癌症的使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
CN111868049B (zh) 2018-01-17 2023-06-30 克林提克斯医药股份有限公司 制备促生长素抑制素调节剂的方法
US12172991B2 (en) * 2018-05-29 2024-12-24 Council Of Scientific & Industrial Research Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof
CA3107168A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
CN109651355A (zh) * 2019-01-24 2019-04-19 广西师范大学 3-(2-苯并五元杂环)-4-(3-二甲胺丙氨基)喹啉衍生物及其制备方法和应用
CN109705037A (zh) * 2019-01-24 2019-05-03 广西师范大学 4-氨基喹啉-3-甲酸酯衍生物及其制备方法和应用
EP3959197A4 (en) * 2019-04-24 2022-10-12 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHODS OF USE THEREOF
WO2021262596A1 (en) 2020-06-22 2021-12-30 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
US20240246941A1 (en) * 2020-07-15 2024-07-25 St. Jude Children's Research Hospital, Inc. Substituted 4-(3-aminoprop-1-yl)aminoquinoline analogs as modulators of melanoma-associated antigen 11 ubiquitin ligase
CN116456968B (zh) 2020-09-09 2026-03-20 克林提克斯医药股份有限公司 生长抑素调节剂的制剂
WO2022087083A1 (en) * 2020-10-21 2022-04-28 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x2 and related products and their use
IL303965A (en) 2020-12-22 2023-08-01 Mekanistic Therapeutics Llc Transmuted heteroaryl aminobenzyl compounds as EGFR and/or PI3K inhibitors
WO2024220236A2 (en) * 2023-04-21 2024-10-24 University Of Georgia Research Foundation, Inc. Hydroxylamine-based bcr-abl1 inhibitors for treatment of cancer
US20250092031A1 (en) * 2023-09-20 2025-03-20 Momentum Therapeutics, Inc. Ripk3 inhibitors and methods of use
WO2025147609A1 (en) * 2024-01-05 2025-07-10 Dewpoint Therapeutics, Inc. Amino quinoline compounds and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1168801A (en) * 1966-05-13 1969-10-29 May & Baker Ltd Quinoline Derivatives
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
JP2007501854A (ja) * 2003-05-27 2007-02-01 ファイザー・プロダクツ・インク 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド［３，４−ｄ］ピリミジン類
DE602005025231D1 (de) 2004-08-10 2011-01-20 Oncotherapy Science Inc Gene und polypeptide in verbindung mit brustkrebserkrankungen
EP2295601A1 (en) 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
EP2295570A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
TW200734327A (en) * 2005-11-03 2007-09-16 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
DK2010496T3 (da) * 2006-04-14 2010-11-08 Astrazeneca Ab 4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer
WO2007139496A1 (en) 2006-05-30 2007-12-06 Clanotech Ab Quinoline derivatives acting as tyrosine kinase inhibitors
WO2008023841A1 (en) 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Breast cancer-associated gene, melk, and its interactions with bcl-g
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CL2007003444A1 (es) * 2006-11-30 2008-06-27 Genentech Inc Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
CN100540551C (zh) * 2007-02-01 2009-09-16 中国药科大学 喹啉衍生物、其制备方法及其医药用途
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2009122180A1 (en) * 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
WO2009155527A2 (en) 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
GEP201706639B (en) * 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
DK2753329T3 (en) * 2012-01-19 2017-10-23 Onco Therapy Science Inc 1,5-NAPHTHYRIDINE INGREDIENTS AS MILK INHIBITORS

Also Published As

Publication number Publication date
MX2013001201A (es) 2013-04-03
DK2597955T3 (en) 2016-03-14
BR112013002182B8 (pt) 2023-02-28
RU2013108865A (ru) 2014-09-10
IL223871A (en) 2016-11-30
BR112013002182A2 (pt) 2016-05-31
US20130217671A1 (en) 2013-08-22
KR101826382B1 (ko) 2018-02-06
JP5849303B2 (ja) 2016-01-27
TW201208686A (en) 2012-03-01
AU2011282588A1 (en) 2013-03-21
RU2582610C2 (ru) 2016-04-27
BR112013002182B1 (pt) 2022-05-03
CA2806332C (en) 2017-11-14
EP2597955B1 (en) 2016-01-20
WO2012016082A1 (en) 2012-02-02
AU2011282588B2 (en) 2016-01-07
HK1184331A1 (zh) 2014-01-24
SG10201505951VA (en) 2015-08-28
CN103153063B (zh) 2016-02-17
EP2597955A1 (en) 2013-06-05
US9120749B2 (en) 2015-09-01
TWI532483B (zh) 2016-05-11
ES2565627T3 (es) 2016-04-06
EP2597955A4 (en) 2014-02-19
KR20130094312A (ko) 2013-08-23
CN103153063A (zh) 2013-06-12
JP2013532727A (ja) 2013-08-19
SG187633A1 (en) 2013-03-28
CA2806332A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
MX342879B (es) Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen.
MX366983B (es) Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen.
IN2015DN00598A (es)
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
EP2550266A4 (en) HETEROCYCLIC COMPOUNDS FOR KINASE INHIBITION
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
IN2014MN02574A (es)
IN2015DN00960A (es)
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
CR20120637A (es) Triazolopiridinas sustituidas
CR20130539A (es) Triazolopiridinas
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
IN2015DN00446A (es)
MX2015017156A (es) Inhibidores de bace.
IN2014DN07996A (es)
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2015007309A (es) Derivado de hidantoina.
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
UY33905A (es) Inhibidores de la catepsina c
MX2013009388A (es) Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl).
MX344429B (es) Nuevos compuestos de hexahidropirroloimidazolona.
UY34518A (es) Composiciones que contienen inhibidores de quinasas
UA86566U (en) N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof

Legal Events

Date Code Title Description
FG Grant or registration